Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected ugandans

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 4, 2014, Pages 456-462

  Martinez, Priscilla ^a,b   Tsai, Alexander C ^c   Muzoora, Conrad ^d   Kembabazi, Annet ^d   Weiser, Sheri D ^e   Huang, Yong ^e   Haberer, Jessica E ^c   Martin, Jeffrey N ^e,f   Bangsberg, David R ^c,d,g,h,i   Hunt, Peter W ^e,f  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Antiretroviral therapy; Depression; Indoleamine 2,3 dioxygenase 1; Sub Saharan Africa; Tryptophan catabolism

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; CONFERENCE PAPER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DIET; PROTEIN INTAKE; PROTEIN RESTRICTION; RURAL HEALTH CARE; SELF REPORT; TREATMENT OUTCOME; UGANDA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; METABOLIC NETWORKS AND PATHWAYS; PLASMA; TREATMENT OUTCOME; TRYPTOPHAN; UGANDA;

EID: 84897998324     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000062     Document Type: Conference Paper

References (62)

1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105
3. Summerfield D. Afterword: Against global mental health. Transcult Psychiatry. 2012;49:519-530
4. Collins PY. Challenges to HIV prevention in psychiatric settings: Perceptions of South African mental health care providers. Soc Sci Med. 2006;63:979-990
5. Nakimuli-Mpungu E, Musisi S, Katabira E, et al. Prevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern Uganda. J Affect Disord. 2011;135:160-167
6. Kaharuza FM, Bunnell R, Moss S, et al. Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav. 2006;10: S105-111
7. Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181-187
8. Tsai AC, Weiser SD, Petersen ML, et al. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010;67:1282-1290
9. Fairfield KM, Libman H, Davis RB, et al. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395-401
10. Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270: 2568-2573
11. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474
12. Page-Shafer K, Delorenze GN, Satariano WA, et al. Comorbidity and survival in HIV-infected men in the San Francisco Meńs Health Survey. Ann Epidemiol. 1996;6:420-430
13. Low-Beer S, Chan K, Yip B, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 2000; 23:295-301
14. Judd FK, Cockram AM, Komiti A, et al. Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: A longitudinal study. Aust N Z J Psychiatry. 2000;34:1015-1021
15. Nakasujja N, Skolasky RL, Musisi S, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry. 2010;10:44
16. Tsai AC, Bangsberg DR, Frongillo EA, et al. Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med. 2012;74:2012-2019
17. Brechtl JR, Breitbart W, Galietta M, et al. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: Impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage. 2001;21:41-51
18. Rabkin JG, Ferrando SJ, Lin SH, et al. Psychological effects of HAART: A 2-year study. Psychosom Med. 2000;62:413-422
19. Maes M, Leonard BE, Myint AM, et al. The new 5-HT hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3- dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:702-721
20. Kohl C, Walch T, Huber R, et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord. 2005;86:135-142
21. Schrocksnadel H, Baier-Bitterlich G, Dapunt O, et al. Decreased plasma tryptophan in pregnancy. Obstet Gynecol. 1996;88:47-50
22. Schrocksnadel K, Widner B, Bergant A, et al. Longitudinal study of tryptophan degradation during and after pregnancy. Life Sci. 2003;72: 785-793
23. Maes M, Lin AH, Ombelet W, et al. Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. Psychoneuroendocrinology. 2000;25:121-137
24. Zangerle R, Widner B, Quirchmair G, et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol. 2002;104:242-247
25. Markus CR. Dietary amino acids and brain serotonin function; implications for stress-related affective changes. Neuromolecular Med. 2008;10: 247-258
26. Weiser SD, Young SL, Cohen CR, et al. Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr. 2011;94:1729S-1739S.
27. Kinyanda E, Hoskins S, Nakku J, et al. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC Psychiatry. 2011;11:205
28. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2:32ra36
29. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav Sci. 1974; 19:1-15
30. Bolton P. Cross-cultural validity and reliability testing of a standard psychiatric assessment instrument without a gold standard. J Nerv Ment Dis. 2001;189:238-242
31. Bolton P, Wilk CM, Ndogoni L. Assessment of depression prevalence in rural Uganda using symptom and function criteria. Soc Psychiatry Psychiatr Epidemiol. 2004;39:442-447
32. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis. 2000;188:662-670
33. Kalichman SC, Sikkema KJ, Somlai A. Assessing persons with human immunodeficiency virus (HIV) infection using the Beck Depression Inventory: Disease processes and other potential confounds. J Pers Assess. 1995;64:86-100
34. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry. 1974;7:79-110
35. Bass JK, Annan J, McIvor Murray S, et al. Controlled trial of psychotherapy for Congolese survivors of sexual violence. N Engl J Med. 2013; 368:2182-2191
36. Hatcher AM, Tsai AC, Kumbakumba E, et al. Sexual relationship power and depression among HIV-infected women in Rural Uganda. PLoS One. 2012;7:e49821
37. Martinez P, Andia I, Emenyonu N, et al. Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in southwest Uganda. Alcohol Clin Exp Res. 2006;30:605-612
38. Tsai AC, Weiser SD, Steward WT, et al. Evidence for the reliability and validity of the internalized AIDS-related stigma scale in rural Uganda. AIDS Behav. 2013;17:427-433
39. Swindale A, Bilinsky P. Household Dietary Diversity Score (HDDS) for Measurement of Household Food Access: Indicator Guide, Version Washington DC, WA: Academy for Educational Development; 2006
40. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data-or tears: An application to educational enrollments in states of India. Demography. 2001;38:115-132
41. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C)-an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789-1795
42. Bradley KA, Bush KR, Epler AJ, et al. Two brief alcohol-screening tests from the Alcohol Use Disorders Identification Test (AUDIT): Validation in a female Veterans Affairs patient population. Arch Intern Med. 2003; 163:821-829
43. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774
44. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5: 2516-2522
45. Grant RS, Naif H, Thuruthyil SJ, et al. Induction of indoleamine 2,3- dioxygenase in primary human macrophages by HIV-1. Redox Rep. 2000;5:105-107
46. Huengsberg M, Winer JB, Gompels M, et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858-862
47. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193
48. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002; 196:459-468
49. Boasso A, Herbeuval JP, Hardy AW, et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007;109:3351-3359
50. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11:312-319
51. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994;51:865-874
52. Maes M, Kubera M, Obuchowiczwa E, et al. Depressiońs multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32:7-24
53. Tsai AC, Bangsberg DR, Emenyonu N, et al. The social context of food insecurity among persons living with HIV/AIDS in rural Uganda. Soc Sci Med. 2011;73:1717-1724
54. Zuch M, Lurie M. A virus and nothing else: The effect of ART on HIVrelated stigma in rural South Africa. AIDS Behav. 2012;16:564-570
55. Castro A, Farmer P. Understanding and addressing AIDS-related stigma: From anthropological theory to clinical practice in Haiti. Am J Public Health. 2005;95:53-59
56. Campbell C, Skovdal M, Madanhire C, et al. We, the AIDS people.: How antiretroviral therapy enables Zimbabweans living with HIV/AIDS to cope with stigma. Am J Public Health. 2011;101:1004-1010
57. Weiser SD, Gupta R, Tsai AC, et al. Changes in food insecurity, nutritional status, and physical health status after antiretroviral therapy initiation in rural Uganda. J Acquir Immune Defic Syndr. 2012;61:179-186
58. Tsai AC, Bangsberg DR, Bwana M, et al. How does antiretroviral treatment attenuate the stigma of HIV Evidence from a Cohort Study in Rural Uganda. AIDS Behav. 2013;17:2725-2731
59. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741
60. de Jong WH, Smit R, Bakker SJ, et al. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solidphase extraction HPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:603-609
61. Badawy AAB. Tryptophan: The key to boosting brain serotonin synthesis in depressive illness. J Psychopharmacol. 2013;10:878-893
62. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra191